Public Funding for Pneumowave Limited

This project aims to address an unmet need in paediatric respiratory and sleep diagnostics. It focuses on the development of PneumoWave's novel respiratory monitoring platform which will be tailored specifically for children. It combines wireless wearable biosensors, mobile 'App'-based software and Artificial Intelligence for non-invasive monitoring, enabling accurate detection of changes in the respiratory pattern which may indicate respiratory distress or apnoea. It will be an easy-to-use, low-cost device that can be worn every night at home, allowing the capture and real-time analysis of longitudinal respiratory physiological data, of a duration not possible with current gold standard diagnostic tests (polysomnography, cardio-respiratory polygraphy) which require overnight hospital admission and invasive equipment, poorly tolerated by children. The device will be tested with patients undergoing routine sleep studies in collaboration with a specialist Paediatric Consultant in Respiratory and Sleep Medicine at NHS Greater Glasgow & Clyde to demonstrate clinical proof of concept. Success will support future product validation in pivotal clinical studies, and Class 2 regulatory clearance in key global markets by 2027\. Adoption of the solution in paediatric sleep diagnostics, driven by demand for improved diagnostic accuracy in sleep disordered breathing and shift towards telemedicine in paediatric respiratory medicine and clinical care, creates significant value across healthcare systems globally, including: * Substantially increasing disease management options for children, addressing current unmet data gaps causing suboptimal diagnostic decision making. * Creating a new market for low-cost longitudinal data capture to monitor disease progression and identify novel digital biomarkers for precision medicine approaches and the development of tailored treatments not currently possible in paediatric respiratory disease. * Future development of real-time adverse event detection and alerting. All of which can be achieved with simple app updates for existing patients with no requirement for hardware updates.

"Opioids are a class of drug prescribed for pain relief or used illicitly for their euphoric effect. In 2016, 23 million prescriptions were issued for opioids in the UK. In that same year, 2,893 people died from accidental opioid overdose. In the USA, there were more than 42,000 deaths. Opioid overdose is now the largest cause of accidental death in most developed countries- far greater than road traffic accidents. Nearly all of these deaths are preventable, either through safer use of opioids or early detection of overdose and administration of a life-saving antidote. Harm from overdose isn't restricted to deaths. For every fatal overdose, there are 20-30 non-fatal overdoses resulting in ambulance call outs, hospital admissions, hospital treatment, loss of productivity and temporary or permanent disability. The estimated annual costs in the UK are in the region of £3.5bn. In the US, the estimated cost is in excess of $500bn. Closely linked to the extent of harm from opioids is the potential for misuse. Opioid users quickly develop tolerance and doses have to be increased rapidly to gain beneficial effects. As the population ages, and with rising health problems, many more patients require the need for pain relief. This has created unprecedented demand for long-term use and an explosion in rates of opioid misuse. Altair Medical Ltd is a health technology start-up company spun out of successful healthcare and IT companies based in Scotland. Our innovative technology continuously monitors patients taking opioids using a small, wireless wearable sensor paired to a smartphone. Data collected by the sensor is analysed by artificial intelligence which monitors drug usage and advises on safe timing of doses, tailored to each individual patient, to reduce the risk of overdose. Should this fail, it detects overdose and alerts first responders to administer naloxone, the powerful opioid antidote. By continuously monitoring high risk opioid users, our technology can also: * identify signs of opioid misuse and facilitate treatment * improve pain control and reduce the risk of side effects * reduce the risk of opioid interactions with other types of medication * send reports to the prescribing doctor to assist in clinical decision making * assist in determining safety for driving. All of which have the potential to dramatically lower the risk of harm from opioid use."